Fabrication of cisplatin-loaded polydopamine nanoparticles via supramolecular self-assembly for photoacoustic imaging guided chemo-photothermal cancer therapy
Source abstract
Abstract
Abstract Nanoscale drug delivery system (nDDS) mediated combinatorial therapy shows great promise in cancer treatment to circumvent the drawbacks of conventional monotherapy. In this study, we reported the development of a supramolecular self-assembly strategy to construct multifunctional nDDS. Cisplatin prodrug (Pt-CD) was successfully loaded onto polydopamine nanoparticles (PDA NPs) through the host-guest supramolecular self-assembly between β-cyclodextrins (β-CD) and adamantyl groups. Two cancer therapeutic modalities, photothermal therapy (PTT) and chemotherapy, were integrated into the as-designed nanoplatform (PDA-Pt NPs) to endow combinatorial anticancer capacity. The excellent photothermal performance and redox responsive cisplatin release behavior of PDA-Pt NPs was fully validated. Moreover, PDA-Pt NPs exhibited photoacoustic imaging capacity for real-time in vivo monitoring of the accumulation of the nanodrug in the tumor site and facilitated the imaging-guided PTT at the optimal treatment window. Ultimately, the combinatorial chemo-photothermal therapy mediated by PDA-Pt NPs exhibited very potent anticancer activity against osteosarcoma 143B cells in vitro and complete ablation of the subcutaneous tumor xenograft in vivo. In conclusion, this study represents an innovative and facile supramolecular self-assembly strategy for fabrication of multifunctional nanotheranostics for efficient combined anticancer therapy, which could further inspire the development of other combinatorial nanotherapeutics.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Gold and Silver Nanoparticles Synthesis and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (60)
Show source-provided references
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2. History of cancer, ancient and modern treatment methods10.4172/1948-5956.100000e2 ↗
3. Mechanisms of drug combinations: interaction and network perspectives10.1038/nrd2683 ↗
4. Strategies for optimizing combinations of molecularly targeted anticancer agents10.1038/nrd2089 ↗
5. Combining immunotherapy and targeted therapies in cancer treatment10.1038/nrc3237 ↗
6. Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy10.1016/j.cell.2017.11.009 ↗
7. Combinational strategy for high-performance cancer chemotherapy10.1016/j.biomaterials.2018.04.027 ↗
8. Advanced diffuse histiocytic lymphoma, a potentially curable disease: results with combination chemotherapy10.1016/S0140-6736(75)91142-3 ↗
9. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial10.1200/JCO.2011.39.5848 ↗
10. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial10.1001/jama.2012.385 ↗
11. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial10.1016/S1470-2045(10)70132-7 ↗
12. p53-reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy10.1158/1078-0432.CCR-17-2709 ↗
13. The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death10.1038/nm.4078 ↗
14. Multifunctional QD-based co-delivery of siRNA and doxorubicin to HeLa cells for reversal of multidrug resistance and real-time tracking10.1016/j.biomaterials.2011.12.035 ↗
15. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy10.1038/nm1196 ↗
16. Cancer nanomedicine: progress, challenges and opportunities10.1038/nrc.2016.108 ↗
17. Cancer nanomedicine: from drug delivery to imaging10.1126/scitranslmed.3005872 ↗
18. Cancer nanotechnology: opportunities and challenges10.1038/nrc1566 ↗
19. Combo” nanomedicine: co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy10.1016/j.addr.2015.10.019 ↗
20. Engineering functional inorganic–organic hybrid systems: advances in siRNA therapeutics10.1039/C7CS00479F ↗
21. Recent advances in nanomaterial-based synergistic combination cancer immunotherapy10.1039/C8CS00896E ↗
22. Dual drug backboned shattering polymeric theranostic nanomedicine for synergistic eradication of patient-derived lung cancer10.1002/adma.201706220 ↗
23. An imagable and photothermal “Abraxane-Like” nanodrug for combination cancer therapy to treat subcutaneous and metastatic breast tumors10.1002/adma.201404308 ↗
24. Nanoformulations for combination or cascade anticancer therapy10.1016/j.addr.2017.06.003 ↗
25. Polymeric nanoparticles with a glutathione-sensitive heterodimeric multifunctional prodrug for in vivo drug monitoring and synergistic cancer therapy10.1002/anie.201801984 ↗
26. Principles of nanoparticle design for overcoming biological barriers to drug delivery10.1038/nbt.3330 ↗
27. Cancer nanomedicines: closing the translational gap10.1016/S0140-6736(14)61457-4 ↗
28. The entry of nanoparticles into solid tumours10.1038/s41563-019-0566-2 ↗
29. Co-delivery of cisplatin prodrug and chlorin e6 by mesoporous silica nanoparticles for chemo-photodynamic combination therapy to combat drug resistance10.1021/acsami.6b03881 ↗
30. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs10.1021/ja803688x ↗
31. Nanoparticle-based targeted drug delivery10.1016/j.yexmp.2008.12.004 ↗
32. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas10.1073/pnas.0607705103 ↗
33. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo10.1073/pnas.1011379108 ↗
34. Systemic delivery of aptamer–drug conjugates for cancer therapy using enzymatically generated self-assembled DNA nanoparticles10.1039/D0NR05652A ↗
35. Targeted ferritin nanoparticle encapsulating CpG oligodeoxynucleotides induces tumor-associated macrophage M2 phenotype polarization into M1 phenotype and inhibits tumor growth10.1039/D0NR04520A ↗
36. Nanotechnology for multimodal synergistic cancer therapy10.1021/acs.chemrev.7b00258 ↗
37. Gold nanorod assisted near-infrared plasmonic photothermal therapy (PPTT) of squamous cell carcinoma in mice10.1016/j.canlet.2008.04.026 ↗
38. Ultrasmall reduced graphene oxide with high near-infrared absorbance for photothermal therapy10.1021/ja2010175 ↗
39. Ultrasmall black phosphorus quantum dots: synthesis and use as photothermal agents10.1002/anie.201506154 ↗
40. Near-infrared (NIR)-absorbing conjugated polymer dots as highly effective photothermal materials for in vivo cancer therapy10.1021/acs.chemmater.6b03738 ↗
41. Delivery of phosphorescent anticancer iridium(III) complexes by polydopamine nanoparticles for targeted combined photothermal-chemotherapy and thermal/photoacoustic/lifetime imaging10.1002/advs.201800581 ↗
42. Nanoparticles in photodynamic therapy10.1021/cr5004198 ↗
43. Near-infrared light induced in vivo photodynamic therapy of cancer based on upconversion nanoparticles10.1016/j.biomaterials.2011.05.007 ↗
44. Two-photon excitation nanoparticles for photodynamic therapy10.1039/C6CS00442C ↗
45. Chemodynamic therapy: tumour microenvironment-mediated Fenton and Fenton-like reactions10.1002/anie.201805664 ↗
46. Synthesis of copper peroxide nanodots for H2O2 self-supplying chemodynamic therapy10.1021/jacs.9b03457 ↗
47. Magnetic vortex nanorings: a new class of hyperthermia agent for highly efficient in vivo regression of tumors10.1002/adma.201405036 ↗
48. Functional nanomaterials for phototherapies of cancer10.1021/cr400532z ↗
49. Gold nanoshell-localized photothermal ablation of prostate tumors in a clinical pilot device study10.1073/pnas.1906929116 ↗
50. Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer10.1038/s41467-018-03473-9 ↗
51. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy10.1038/ncomms13193 ↗
52. Black phosphorus nanosheets as a robust delivery platform for cancer theranostics10.1002/adma.201603276 ↗
53. Multipronged design of light-triggered nanoparticles to overcome cisplatin resistance for efficient ablation of resistant tumor10.1021/acsnano.5b05097 ↗
54. Supramolecular self-assembled nanoparticles for chemo-photodynamic dual therapy against cisplatin resistant cancer cells10.1039/C4CC08583C ↗
55. Dopamine-melanin colloidal nanospheres: an efficient near-infrared photothermal therapeutic agent for in vivo cancer therapy10.1002/adma.201204683 ↗
56. Cyclodextrin-based host–guest supramolecular nanoparticles for delivery: from design to applications10.1021/ar500055s ↗
57. The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs10.1021/acs.chemrev.5b00597 ↗
58. CAIXplatins: highly potent platinum(IV) prodrugs selective against carbonic anhydrase IX for the treatment of hypoxic tumors10.1002/anie.202005362 ↗
59. Interfering in apoptosis and DNA repair of cancer cells to conquer cisplatin resistance by platinum(iv) prodrugs10.1039/D0SC00197J ↗
60. Photoacoustic tomography: in vivo imaging from organelles to organs10.1126/science.1216210 ↗